Skip to main content
Veterinary Medicines

CLOXALENE PLUS 95,3 mg/ml + 47,8 mg/ml sospensione iniettabile per bovini, equini, suini, cani e gatti

Authorised
  • Ampicillin sodium
  • Dicloxacillin sodium

Product identification

Medicine name:
CLOXALENE PLUS 95,3 mg/ml + 47,8 mg/ml sospensione iniettabile per bovini, equini, suini, cani e gatti
Active substance:
  • Ampicillin sodium
  • Dicloxacillin sodium
Target species:
  • Cattle
  • Horse
  • Pig
  • Dog
  • Cat
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Ampicillin sodium
    95.30
    milligram(s)
    /
    1.00
    millilitre(s)
  • Dicloxacillin sodium
    47.80
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        4
        day
      • Milk
        48
        hour
    • Horse
      • Meat and offal
        14
        day
    • Pig
      • Meat and offal
        3
        day
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CA51
Authorisation status:
  • Valid
Authorised in:
  • Italy
Available in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Ministry Of Health
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 12/01/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."